Compare Altria Group Inc (MO) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Altria Group Inc vs ResMed Inc. — how do they compare? Altria Group Inc trades at $71.82 (market cap $119.25B), while ResMed Inc. trades at $228.72 (market cap $31.89B). The key difference: Altria Group Inc is far larger — about 3.7× ResMed Inc.'s market cap, and Altria Group Inc pays the higher dividend (6.22%). Which is the better fit depends on your goals — on Pluang, investors hold Altria Group Inc for 154 Days and ResMed Inc. for 51 Days on average.
| MO | RMD | |
|---|---|---|
Market Cap | $119.25B | $31.89B |
Volume | 11,178,169 | 618,314 |
Sector | Consumer Staples | Health |
52-Week High | $74.92 | $277.88 |
52-Week Low | $54.72 | $182.82 |
Typical Hold Time | 154 Days | 51 Days |
Enterprise Value | $141.46B | $31.24B |
Dividend Yield | 6.22% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Altria Group (MO) trades at $69.39, up 1.22% today, near the analyst consensus price target of $69.71. The stock shows a bullish technical trend with strong moving average signals, while oscillators remain neutral. Fundamentally, the company maintains robust profitability with a 39% net income margin and strong cash flow, though revenue has been slightly declining. Recent earnings have been mixed, with one beat and two misses in the last three quarters. A high dividend yield of approximately 6.6% is supported by 60 consecutive annual increases, but the balance sheet shows negative shareholder equity.
The outlook for MO balances income appeal against structural challenges. The high dividend and bullish analyst consensus (61.5% buy ratings) offer value for income investors, but risks include declining core tobacco sales, regulatory pressures on nicotine products, and a leveraged balance sheet. Earnings growth and smoke-free product adoption are critical for sustained performance.
ResMed (RMD) trades at $228.37, up 1.06% today, with a bullish technical signal and strong fundamentals. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15B in 2025, with a robust net income margin of 26.94%. Recent news highlights management's presentation at the Morgan Stanley Healthcare Conference and an upcoming Q1 2027 earnings report.
The outlook is positive, supported by earnings growth targets of 12-14% and a consensus price target of $242.70. Key risks include competitive pressures and ongoing legal investigations. Institutional buying activity and analyst upgrades reflect confidence, but investors should monitor execution against growth targets and any developments from the legal probe.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
